Clinical Trial Update: Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

A Phase 3, double-masked trial of AR-13324 ophthalmic solution in ocular hypertension and open-angle glaucoma has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• AR-13324 ophthalmic solution (netarsudil)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Status: COMPLETED | Results posted: 2018-04-13